when is semaglutide off patent Novo Nordisk losing Canadian protection on a blockbuster drug after not paying a small fee Your Questions Answered: Off-patent Semaglutide

Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)

These drugs are effective only while active in your system, and stopping treatment allows hunger and fullness signals to revert to their pre-treatment state

Balancing these dynamics involves maintaining efficient supply chains and skilled personnel, which can impact costs

But for weekly dosing of long-half-life medications like GLP-1 agonists, the one-compartment model produces curves that closely match actual measured blood levels